CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics

CytomX Therapeutics, Inc. (CTMX): $2.20

0.01 (+0.46%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

B

Add CTMX to Watchlist
Sign Up

CTMX Price/Volume Stats

Current price $2.20 52-week high $2.86
Prev. close $2.19 52-week low $1.04
Day low $2.20 Volume 745
Day high $2.20 Avg. volume 877,632
50-day MA $1.89 Dividend yield N/A
200-day MA $1.57 Market Cap 149.01M

CTMX Stock Price Chart Interactive Chart >

CTMX POWR Grades

  • CTMX scores best on the Growth dimension, with a Growth rank ahead of 95.54% of US stocks.
  • The strongest trend for CTMX is in Value, which has been heading up over the past 26 weeks.
  • CTMX ranks lowest in Momentum; there it ranks in the 10th percentile.

CTMX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CTMX is -1.47 -- better than just 4.92% of US stocks.
  • CTMX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.57% of US stocks.
  • With a year-over-year growth in debt of -29.61%, CYTOMX THERAPEUTICS INC's debt growth rate surpasses merely 10.9% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to CYTOMX THERAPEUTICS INC, a group of peers worth examining would be CRDF, DBVT, HYLN, AGEN, and MRUS.
  • CTMX's SEC filings can be seen here. And to visit CYTOMX THERAPEUTICS INC's official web site, go to www.cytomx.com.

CTMX Valuation Summary

  • In comparison to the median Healthcare stock, CTMX's price/sales ratio is 66.67% lower, now standing at 1.4.
  • Over the past 100 months, CTMX's price/sales ratio has gone down 59.9.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2023-12-29 1.4 -2.0 -3.5 -3.3
CTMX 2023-12-28 1.4 -2.0 -3.5 -3.3
CTMX 2023-12-27 1.4 -2.0 -3.5 -3.3
CTMX 2023-12-26 1.3 -1.9 -3.4 -3.1
CTMX 2023-12-22 1.3 -1.9 -3.3 -3.0
CTMX 2023-12-21 1.3 -1.8 -3.2 -2.9

CTMX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at -14.07%.
  • Its 3 year revenue growth rate is now at -5.43%.
  • The 3 year net cashflow from operations growth rate now stands at -30.48%.
CTMX's revenue has moved up $5,523,000 over the prior 15 months.

The table below shows CTMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 71.943 -140.586 -97.593
2022-06-30 72.615 -136.442 -96.881
2022-03-31 70.738 -130.404 -91.94
2021-12-31 69.573 -119.031 -83.609
2021-09-30 66.219 -105.266 -72.082
2021-06-30 66.42 -100.244 -64.208

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
  • JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CytomX Therapeutics, Inc. (CTMX) Company Bio


CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.


CTMX Latest News Stream


Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream


Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at ww

Yahoo | December 21, 2023

Investors in CytomX Therapeutics (NASDAQ:CTMX) have unfortunately lost 90% over the last five years

CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders should be happy to see the share price up 26% in the last month...

Yahoo | December 11, 2023

Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study

Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.

Yahoo | December 6, 2023

Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data

Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.

Yahoo | December 5, 2023

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

Yahoo | December 5, 2023

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo -2.22%
3-mo 41.94%
6-mo 70.54%
1-year 43.32%
3-year -71.01%
5-year -79.53%
YTD 41.94%
2023 -3.13%
2022 -63.05%
2021 -33.89%
2020 -21.18%
2019 -44.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!